Special Issue "Antiviral Drug Combinations"
Deadline for manuscript submissions: 31 August 2020.
Interests: antiviral agents; broad-spectrum antivirals; antiviral response; innate immunity; adaptive immunity
Viral diseases are the leading cause of morbidity and mortality in developing countries. Antiviral agents are key players in the control of viral diseases. Antiviral agents could be combined to obtain synergistic or additive effects against certain viruses. Combination therapies became a standard for the treatment of HIV and HCV infections. These include abacavir/dolutegravir/lamivudine (Triumeq), darunavir/cobicistat/emtricitabine/tenofovir (Symtuza), lopinavir/ritonavir (Kaletra), ledipasvir/sofosbuvir, and sofosbuvir/velpatasvir. Drug combinations could also be used to target several viral infections or co/infections. Such combinations could serve as frontline therapeutics against poorly characterized emerging viruses or re-emerging drug-resistant viral strains. We thus invite submission of original research manuscripts and review articles that cover any aspects of antiviral drug combinations and related topics.
I look forward for your contribution.
Prof. Dr. Denis E. Kainov
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Antiviral agents
- Antiviral drug combinations
- Broad-spectrum antivirals
- Antiviral response
- Innate immunity
- Adaptive immunity